The iRR6 model refines risk stratification for intermediate-1 myelofibrosis patients, incorporating ruxolitinib dosing, spleen reduction, and transfusion needs. Validation in an external cohort ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback